These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34195457)

  • 1. Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy.
    L Kandaurava S; S Baslyk K; A Migas A; V Hill A; I Bydanov O; A Mishkova V; V Aleinikova O
    Curr Med Mycol; 2020 Dec; 6(4):27-34. PubMed ID: 34195457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
    Imataki O; Yamaguchi K; Uemura M; Fukuoka N
    Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.
    Liu X; Su H; Tong J; Chen J; Yang H; Xiao L; Hu J; Zhang L
    Medicine (Baltimore); 2017 Oct; 96(42):e8039. PubMed ID: 29049191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Application Study of Voriconazole and Its Metabolites Concentration Monitoring in Allogeneic Hematopoietic Stem Cell Transplantation Patients].
    Wang HC; Wang L; Li M; Shi L; Sun HH; Liu HX; Ou HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):945-951. PubMed ID: 38926993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment with voriconazole for invasive fungal infection during chemotherapy for leukemia: doses and plasma concentration of voriconazole in children].
    Fukushima K; Fujisawa M; Nakajima D; Matsunaga T; Hagisawa S; Kurosawa H; Sugita K; Arisaka O
    Rinsho Ketsueki; 2007 May; 48(5):402-6. PubMed ID: 17571586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of voriconazole oral dosage in Japan].
    Hamada Y; Kawasumi N; Hirai J; Yamagishi Y; Mikamo H
    Jpn J Antibiot; 2014 Oct; 67(5):279-84. PubMed ID: 25566590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience.
    Atoui A; Omeirat N; Fakhreddine O; El Alam R; Kanafani Z; Abou Dalle I; Bazarbachi A; El-Cheikh J; Kanj SS
    J Fungi (Basel); 2021 Oct; 7(11):. PubMed ID: 34829213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole Concentrations in Cerebrospinal Fluid During Prophylactic Use in Children with Acute Myelogenous Leukemia.
    Kobayashi R; Sano H; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    Pediatr Infect Dis J; 2016 Mar; 35(3):297-8. PubMed ID: 26650112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting voriconazole concentration to dose ratio changes according to route of administration.
    Chen C; Xu T; Zhou K; Zhu S
    Eur J Hosp Pharm; 2023 Dec; 31(1):31-35. PubMed ID: 35273002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of liposomal amphotericin against febrile neutropenia in pediatric patients receiving prophylactic voriconazole.
    Kobayashi R; Matsushima S; Hori D; Sano H; Suzuki D; Kishimoto K; Nakano T; Yanagi M; Kodama K; Kobayashi K
    Pediatr Int; 2021 May; 63(5):550-555. PubMed ID: 32869416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Implementation of Loading Dose of Voriconazole from 2010 to 2019 and Influencing Factors of Loading Dose Based on a Japanese Administrative Claim Database: A Retrospective Cohort Study.
    Inose R; Goto R; Shimoki M; Ohmagari N; Muraki Y
    Biol Pharm Bull; 2023; 46(12):1838-1841. PubMed ID: 38044104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
    Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
    Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.
    Mishra P; Agrawal N; Bhurani D; Agarwal NB
    Indian J Hematol Blood Transfus; 2020 Jan; 36(1):64-70. PubMed ID: 32174692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.
    Tsutsumi I; Kunisawa S; Yoshida C; Seki M; Komeno T; Fushimi K; Morita S; Imanaka Y
    Int J Clin Oncol; 2019 Nov; 24(11):1449-1458. PubMed ID: 31300904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study.
    Miyakawa-Tanaka K; Suzuki J; Hirasawa Y; Nakamura S; Takeda K; Narumoto O; Matsui H
    J Infect Chemother; 2023 Jul; 29(7):683-687. PubMed ID: 36965708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.